Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 October 2004, Vol. 104, No. 7, pp. 1920.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edinger, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Edinger, M.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow


InsideBlood

TRANSPLANTATION

Comment on Miura et al, page 2187

Immunoregulation in human bone marrow transplantation?

Matthias Edinger

UNIVERSITY HOSPITAL REGENSBURG

Quantification of Foxp3 messenger RNA was used to evaluate the reconstitution of the regulatory T-cell compartment after bone marrow transplantation.

CD4+ T cells that constitutively express the alpha chain of the interleukin 2 (IL-2) receptor (CD25) are enriched in thymus-derived suppressor cells that preferentially express Foxp3, a forkhead/winged-helix transcriptional regulator.1 In the study presented by Miura and colleagues, Foxp3 mRNA was quantified in mononuclear cells (MNCs) to monitor regulatory T-cell reconstitution after autologous or allogeneic bone marrow transplantation (BMT). The authors detected lower Foxp3 expression levels in patients with graft-versus-host disease (GVHD) compared with patients without GVHD after allogeneic BMT as well as in breast cancer patients developing an autoimmune syndrome (autologous GVHD) that was purposely induced by the administration of cyclosporine A after highdose chemotherapy. Diminished Foxp3 expression correlated with a low number of T-cell receptor excision circles (TRECs) in MNCs from GVHD patients, suggesting that regulatory T cells regenerate from thymic precursors and that thymic dysfunction in autologous and allogeneic GVHD results in an impaired output of suppressor T cells, thereby perpetuating disease. Interestingly, response to GVHD therapy was accompanied by a recovery of the Foxp3+ T-cell pool in a limited number of serially examined patients.

This is the first report suggesting that suppressor cell–mediated regulation may play an important role in human GVHD pathophysiology. Although the results should be interpreted with caution, since a mere positive or negative correlation does not prove (or disprove) the biologic relevance of an observed phenomenon, they are well supported by several animal studies demonstrating a central role for regulatory T cells in the development and maintenance of peripheral tolerance to self-antigens and alloantigens.2 Sakaguchi and colleagues3 initially revealed the significance of CD4+CD25+ regulatory T cells for the protection from autoimmune diseases in mice that underwent thymectomy early in life. Similarly, adoptively transferred rat CD25+ regulatory T cells protect from autologous GVHD caused by cyclosporine treatment of syngeneic BM recipients.4 In murine models of allogeneic BMT, Johnson et al5 demonstrated that CD4+CD25+ regulatory T cells develop from bone marrow–derived T-cell precursors and depend on thymic maturation. Once generated, they modulate GVHD induced by the delayed infusion of donor lymphocytes.6 Furthermore, several groups reported that the cotransplantation of large numbers of donortype CD4+CD25+ regulatory T cells at the time of BMT protects recipients from lethal GVHD induced by nonregulatory T cells.6 Thus, there is increasing evidence for T-cell–mediated immunoregulation after allogeneic BMT, and the findings of Miura et al should encourage clinicians to further explore those mechanisms for the development of improved hematopoietic stem cell transplantation strategies. {blacksquare}

References

  1. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299: 1057-1061.[Abstract/Free Full Text]

  2. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3: 199-210.[CrossRef][Medline] [Order article via Infotrieve]

  3. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med. 1996;184: 387-396.[Abstract/Free Full Text]

  4. Wu DY, Goldschneider I. Tolerance to cyclosporin A-induced autologous graft-versus-host disease is mediated by a CD4+CD25+ subset of recent thymic emigrants. J Immunol. 2001;166: 7158-7164.[Abstract/Free Full Text]

  5. Johnson BD, Konkol MC, Truitt RL. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant. 2002;8: 525-535.[CrossRef][Medline] [Order article via Infotrieve]

  6. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196: 389-399.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Association of Foxp3 regulatory gene expression with graft-versus-host disease
Yuji Miura, Christopher J. Thoburn, Emilie C. Bright, Michele L. Phelps, Tahiro Shin, Elizabeth C. Matsui, William H. Matsui, Sally Arai, Ephraim J. Fuchs, Georgia B. Vogelsang, Richard J. Jones, and Allan D. Hess
Blood 2004 104: 2187-2193. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edinger, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Edinger, M.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020